A LinkedIn post from Neuromod Devices Ltd highlights the company’s presence at The Sound Exchange 26 conference at Accor Stadium in Sydney, where representative Andrew Coulter is engaging with audiology professionals. The post cites data from The Medical Journal of Australia indicating that 33% of Australians have experienced tinnitus, with 17% living with constant tinnitus symptoms.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post underscores that its Lenire device has shown significant tinnitus relief across three large-scale clinical trials and in real-world outcomes, positioning the product as a home-based treatment option. For investors, this focus on clinical validation and direct engagement with clinicians in a market with substantial tinnitus prevalence suggests ongoing efforts to drive professional adoption, which could support long-term revenue growth and strengthen Neuromod’s competitive position in the tinnitus-treatment segment.